4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,258.44 in Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 1,922 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $10.02, for a total value of $19,258.44. Following the completion of the sale, the insider directly owned 1,057,231 shares of the company’s stock, valued at approximately $10,593,454.62. This represents a 0.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

4D Molecular Therapeutics Price Performance

4D Molecular Therapeutics stock traded down $0.40 during mid-day trading on Tuesday, hitting $9.31. The company’s stock had a trading volume of 1,075,089 shares, compared to its average volume of 705,181. The firm’s 50 day moving average is $9.53 and its 200 day moving average is $9.28. The company has a market cap of $486.69 million, a PE ratio of -3.62 and a beta of 2.75. 4D Molecular Therapeutics, Inc. has a 52-week low of $3.55 and a 52-week high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The business had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. As a group, analysts forecast that 4D Molecular Therapeutics, Inc. will post -3.74 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in FDMT. Janus Henderson Group PLC raised its stake in shares of 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after acquiring an additional 2,882,508 shares in the last quarter. State Street Corp raised its stake in shares of 4D Molecular Therapeutics by 197.5% in the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock valued at $20,167,000 after acquiring an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. raised its stake in shares of 4D Molecular Therapeutics by 23.9% in the 4th quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in shares of 4D Molecular Therapeutics by 605.8% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after acquiring an additional 1,060,156 shares in the last quarter. Finally, Evergreen Quality Fund GP Ltd. bought a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $7,136,000. 99.27% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

FDMT has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Royal Bank Of Canada raised their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Monday, April 20th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.88.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.